Alpha CR Solutions manages the full regulatory and ethics submission lifecycle, from CTA preparation through SAHPRA approval, IRB and IEC submissions, to ongoing compliance.
Navigating the South African regulatory and ethics landscape demands more than form-filling. It requires deep institutional knowledge, established relationships with health authorities, and a rigorous quality framework.
Our team integrates directly into your study operations, managing submissions to the South African Health Products Regulatory Authority (SAHPRA) and ethics committees registered with the National Health Research Ethics Council (NHREC).
Whether you are an emerging biotech conducting your first Phase I trial in South Africa, or a global sponsor expanding into Africa, we tailor our regulatory strategy to your timeline, budget, and therapeutic area.
Get in TouchAlpha CR Solutions manages every phase of the South African regulatory and ethics approval process, giving you a single point of accountability from submission to site activation.
ICF Development
Informed consent documents prepared to SAHPRA and ICH standards.
SAHPRA CTA Submission
Full CTA compiled including IMPD, IB and protocol synopsis.
IRB & IEC Submissions
Parallel submissions to NHREC IRBs and site IECs.
Dual Approval
Coordinating SAHPRA and ethics approvals simultaneously.
Site Initiation
GCP training, SDR setup and SIV support.
Ongoing Compliance
Amendments, annual reports and safety notifications.
Comprehensive support across the full spectrum of South African clinical trial regulatory requirements.
End-to-end management of all submissions to the South African Health Products Regulatory Authority.
Full lifecycle management of IRB and IEC submissions in compliance with NHREC requirements.
Experienced CRAs supporting sites from qualification through close-out to ICH E6(R3) standards.
Direct experience managing submissions across South African and international regulatory frameworks.
Category D is SAHPRA's category for complementary medicines. Companies that manufacture, import, export, wholesale or distribute them are licensed by SAHPRA under section 22C(1)(b) of the Medicines and Related Substances Act, 1965. We prepare and submit new applications, amendments and renewals for you. See SAHPRA's complementary medicines guidance.
For manufacturers of Category D complementary medicines, covering manufacture, import and export. SAHPRA's form is titled "Licence to manufacture, import or export Complementary Medicines (Category D)".
For companies that import or export Category D complementary medicines. SAHPRA's form is titled "Licence to import or export Complementary Medicines (Category D)".
For companies that act as a wholesaler of, or distribute, Category D complementary medicines. SAHPRA's form is titled "Licence to act as a wholesaler of or distribute Complementary Medicines (Category D)".
Changes to an existing Category D licence. DA01 is the "Amendment of existing Category D licence" and includes the option to upload only a product list showing deleted or new medicines. DA02 is the product list for an existing section 22C(1)(b) licence that already states Category D medicines. Holders of manufacture, import, export, wholesale and distribution licences can use both.
Renewal applications for existing licences. DR01 renews a manufacture, import or export licence, DR02 an import or export licence, and DR03 a wholesale or distribution licence.
We prepare and submit your application, amendment or renewal, respond to SAHPRA's queries and liaise with the authority on your behalf.
Discuss your licence application